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Abstract
Introduction Unclassified variants (UVs) of unknown clinical
significance are frequently detected in the BRCA2 gene. In this
study, we have investigated the potential pathogenic relevance
of the recurrent UV S384F (BRCA2, exon 10).
Methods For co-segregation, four women from a large kindred
(BN326) suffering from breast cancer were analysed. Moreover,
paraffin-embedded tumours from two patients were analysed for
loss of heterozygosity. Co-occurrence of the variant with a
deleterious mutation was further determined in a large data set
of 43,029 index cases. Nature and position of the UV and
conservation among species were evaluated.
Results We identified the unclassified variant S384F in three of
the four breast cancer patients (the three were diagnosed at 41,
43 and 57 years of age). One woman with bilateral breast
cancer (diagnosed at ages 32 and 50) did not carry the variant.
Both tumours were heterozygous for the S384F variant, so loss
of the wild-type allele could be excluded. Ser384 is not located
in a region of functional importance and cross-species
sequence comparison revealed incomplete conservation in the
human, dog, rodent and chicken BRCA2 homologues. Overall,
the variant was detected in 116 patients, five of which co-
occurred with different deleterious mutations. The combined
likelihood ratio of co-occurrence, co-segregation and loss of
heterozygosity revealed a value of 1.4 × 10-8  in favour of
neutrality of the variant.
Conclusion Our data provide conclusive evidence that the
S384F variant is not a disease causing mutation.
Introduction
Inherited mutations in the BRCA1 and BRCA2 genes predis-
pose to early breast and ovarian cancer. Besides clear patho-
genic mutations (nonsense mutations or insertions and
deletions leading to truncated proteins), many unclassified var-
iants also exist, for example, missense mutations of unknown
relevance that constitute about 30% of all mutations detecta-
ble in the BRCA1 or BRCA2 genes [1,2].
A lack of functional assays has hampered the conclusive vali-
dation of the consequences of these variants. This raises vari-
ous problems for the clinical management, genetic counselling
and personal life planning of people who carry such an unclas-
sified BRCA1/2 variant. To characterise the potential patho-
genic relevance of unclassified variants, co-segregation, co-
occurrence, loss of heterozygosity (LOH) analysis, cross-spe-
cies comparison, biochemical characterisation and occur-
rence in a healthy control cohort can be used [3,4]. We have
investigated the common variant S384F (BRCA2, exon 10) in
a large kindred (BN326) using these approaches.
GCHBOC = German Consortium for Hereditary Breast and Ovarian Cancer; LOH = loss of heterozygosity; LR = likelihood ratio; PCR = polymerase 
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Materials and methods
Co-segregation
A large kindred with the BRCA2 variant S384F [GenBank
U43746] was recruited at the Centre for Familial Breast and
Ovarian Cancer located at the universities of Cologne and
Bonn (Fig. 1a). Blood samples were available from four women
suffering from breast cancer (IDs 326.1, 326.2, 326.3 and
326.4). The study was permitted by the local ethics committee
and written consent was obtained from all patients. DNA was
extracted from peripheral leukocytes using a conventional phe-
nol-chloroform protocol. Mutation analysis was performed as
described before [2]. Segregation analysis in the BRCA2
gene was restricted to a 171 base pair fragment of exon 10
spanning the variant. For amplification, PCR was performed
under the following conditions: 95°C for 30 s, 54°C for 30 s,
72°C for 1 minute, 35 cycles (Perkin Elmer, model 9600, Shel-
ton, CT, USA); forward primer, 5'-gca aac gct gat gaa tgt g-3';
reverse primer 5'-ggc caa aga cgg tac aac t-3'. PCR products
from leukocyte and tumour DNA were directly sequenced for-
ward and reverse on a semiautomated sequencer (Applied
Biosystems, model 377, Foster City, USA) using the ABI
PRISM BigDye™ Terminator Cycle Sequencing Ready Reac-
tion Kit version 1.1 (Applied Biosystems), according to the
manufacturer's protocol.
Co-occurrence
Data on co-occurrence of the variant with deleterious muta-
tions in the BRCA2 gene were provided by the German Con-
sortium for Hereditary Breast and Ovarian Cancer
(GCHBOC) and by Myriad Genetic Laboratories, where
3,029 and 40,000 patients suffering from familial breast and/
or ovarian cancer had been tested.
Loss of heterozygosity analysis
Paraffin-embedded tumour samples from two affected women
(ID 326.1 and ID 326.2, Fig. 1a) were available. After morpho-
logic evaluation on 4 µm hematoxylin and eosin-stained sec-
tions, manual microdissection was performed to enrich tumour
cells to >90%. DNA was extracted from two 10 µm sections
using an all-tissue DNA-extraction kit according to the manu-
facturer's protocol (GEN-IAL, Troisdorf, Germany). LOH anal-
ysis was performed by direct sequencing as described above.
In the case of LOH of the wild-type allele, the tumour is
hemizygous for the variant.
Statistical analysis
A multifactorial model was used to calculate a combined like-
lihood ratio [3,4]. For analysis of co-segregation, the linkage
program was applied [5]. For analysis of co-occurrence, we
followed Goldgar's assumption that compound heterozygotes
or homozygotes for deleterious mutations in the BRCA genes
are extremely rare [3]. The probability of the observation of no
LOH of the wild-type allele, in the case that the mutation is del-
eterious, was defined as 5% [6], whereas the observation of
no LOH of the wild-type allele, in the case that the mutation is
not deleterious, was defined as 80% [7].
Results
The variant S384F was first identified in patient 326.1, who
suffered from uni-lateral breast cancer at 43 years of age. Fur-
ther analysis showed that patients 326.2 and 326.4 (uni-lat-
eral breast cancers at 41 and 57 years of age, respectively)
were also carriers of the S384F variant. In contrast, a patient
with bilateral breast cancer (ID326.3, diagnosed at 32 and 50
years of age) did not exhibit the variant. A complete BRCA1
and BRCA2 analysis was performed in this patient in order to
exclude a second mutation. Carrier status and degree of kin-
ship of all persons tested for the S384F variant are shown in
Fig. 1a. Using the approach of Thompson et al. [4] and Lath-
rop et al. [5], we analysed the co-segregation of the variant
and the disease. We calculated a likelihood ratio of LRcoseg =
3.236 that the variant is causal for the disease.
The variant was detected in 109 patients tested by Myriad
Genetic Laboratories and in 9 patients tested by the GCH-
BOC and co-occurred five times with the different deleterious
mutations Q258X, K2013X, S2219X, 3036del4 (Myriad) and
2046X (GCHBOC). It could not be detected in 200 healthy
control women over the age of 60 years. Using the algorithm
of Goldgar et al. [3] the likelihood ratio was LRcooc  =
0.00000111 in favour of neutrality of the variant. Combining
co-occurrence and co-segregation analysis revealed a likel-
hood ratio of LRcoseg+cooc = 0.0000036.
Tumour DNA from two patients (ID 326.1, 326.2) carrying the
unclassified variant were heterozygous; loss of the wild-type
allele could thus be excluded (Fig. 1b). Considering the differ-
ent frequencies of occurrence of LOH in familial (95%) and
sporadic breast carcinomas (20%) gave a likelihood ratio of
LRLOH = 0.0039 for the variant to be neutral. If one assumes
LOH as an independent event, the total likelihood ratio rises to
LRtotal = 1.4 × 10-8 in favour of neutrality (Table 1).
Considering the position of the variant, codon 384 is not
located in a region of functional importance. Cross-species
sequence comparison revealed good alignment of the human,
dog, rodent and chicken BRCA2 amino acid homologues (Fig.
2). Whereas human (U43746) and dog (NP001006654)
BRCA2 homologues at positions 384 and 375 both encode a
serine, however, mouse (U89652) and rat (U89653) BRCA2
homologues at positions 376 and 374 encode a cysteine. The
chicken (NP989607) BRCA2  homologue at position 400
encodes for a valine. Biochemical evaluation revealed that the
S384F variant results in a non-conservative substitution of a
hydrophilic amino acid (Ser) by a hydrophobic one (Phe). Both
are, however, uncharged.Available online http://breast-cancer-research.com/content/7/5/R775
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Figure 1
Segregation and loss of heterozygosity analysis of the S384F variant (BRCA2, exon 10) in kindred ID 326 Segregation and loss of heterozygosity analysis of the S384F variant (BRCA2, exon 10) in kindred ID 326. (a) Patients ID 326.1, ID 326.2 and ID 
326.4 were heterozygous for the variant. In contrast, a patient with bilateral breast cancer (ID 326.3) diagnosed at 32 and 50 years of age did not 
carry the variant. Filled symbols indicate individuals with breast cancer. UV+, patients heterozygous for the S384F variant; UV-, patients homozygous 
for the wild-type allele. (b) Arrows indicate patients from whom tumour samples were available. In the tumours of both ID 326.1 (left) and ID 326.2 
(right), loss of the wild-type allele could be excluded.Breast Cancer Research    Vol 7 No 5    Wappenschmidt et al.
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Discussion
The germline variant S384F was previously classified by us as
a variant of unknown significance. Segregation analysis
revealed incomplete segregation in a large kindred. While
three women affected by breast cancer carried the variant, one
was lacking it. The latter was affected by bi-lateral breast can-
cer at 32 and 50 years of age so it is very unlikely that this
patient suffered from sporadic breast cancer, indicating that
the underlying mutation is not yet identified. Using the
approach of Thompson et al. [4] we calculated a LR of 3.236
in favour of the variant being deleterious.
The variant could be identified in 116 of 43,029 patients with
a history of familial breast cancer. In this cohort, the variant co-
occurred five times with different deleterious mutations, indi-
cating that the variant is located in trans. In accordance with
Goldgar  et al. [3], we assumed that biallelic deleterious
BRCA2 mutations are extremely rare as they generally cause
Fanconi anemia type D1 leading to early childhood death.
Based on a proposed probability of p2 = 0.001 that an individ-
ual with the variant also carries a deleterious mutation in trans,
Goldgar et al. suggested that a LR >1.0 is in favour of the var-
iant being deleterious whereas a LR <0.01 argues in favour of
the variant being neutral. For the S384F variant, we calculated
a combined LR for co-occurrence and co-segragation of
0.0000036, leading to the conclusion that the variant is
neutral.
Recently, Osorio and co-workers [6] evaluated the rate and
significance of LOH at the BRCA loci in 47 tumour samples
from high risk patients with familial breast cancer. Their results
suggest that LOH of the wild-type allele is a common mecha-
nism of inactivation of the BRCA genes (95%) and that LOH
analysis can be used to clarify the relevance of variants of
unknown significance. In contrast, LOH of the BRCA genes
occurs in only 20% of sporadic breast carcinomas [7]. Based
on these rates, we again calculated a LR in favour of the variant
being neutral from the observation of the two patients (326.1
and 326.2) who were heterozygous.
Also, the position and the nature of the amino acid substitution
provide evidence for neutrality of the variant: the serine residue
at codon 384 is not located in a protein domain of critical func-
tion [8]; and, although the unclassified variant results in a non-
conservative substitution of a hydrophilic amino acid (Ser) by
a hydrophobic one (Phe), both amino acids are uncharged.
Additionally, both cysteine in rodents and valine in chicken are
large hydrophobic amino acids with uncharged residues sug-
gesting that these substitutions are not functionally relevant.
The degree of conservation of BRCA2 homologues between
species, however, is incomplete.
Conclusion
To summarize, the combined use of co-segregation, co-occur-
rence and LOH analysis, as well as the position and nature of
the amino acid substitution, provides strong evidence that the
S384F variant is not the disease causing mutation in family
BN326. We cannot, however, exclude that the variant may act
as a modifying or low penetrance gene that may exhibit incom-
plete segregation and retention of the wild-type allele, as has
been demonstrated for the CHEK2 gene [9,10].
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Table 1
Likelihood ratios for the S384F variant
LR for S384F (BRCA2)
Co-segregation 3.236
Co-occurrence 0.00000111
Loss of heterozygosity 0.00391
Overall LR 1.4 × 10-8
An overall likelihood ratio (LR) of <0.01 is considered to prove that 
the variant is neutral [3].
Figure 2
Cross-species comparison of the BRCA2 homologue: Alignment of the  predicted BRCA2 amino acid sequence of human (U43746), dog  (NP001006654), mouse (U89652), rat (U89653) and chicken  (NP989607) Cross-species comparison of the BRCA2 homologue: Alignment of the 
predicted BRCA2 amino acid sequence of human (U43746), dog 
(NP001006654), mouse (U89652), rat (U89653) and chicken 
(NP989607). Amino acid sequences identical in humans, dog, rodents 
and chicken are in red. The asterisk indicates the position of the S384F 
variant.Available online http://breast-cancer-research.com/content/7/5/R775
R779
the family who took part in the study and gave written consent for publi-
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